271 related articles for article (PubMed ID: 22290257)
21. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
23. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
Ahir BK; Engelhard HH; Lakka SS
Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
[TBL] [Abstract][Full Text] [Related]
24. Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy.
Reardon DA; Wen PY; Desjardins A; Batchelor TT; Vredenburgh JJ
Expert Opin Biol Ther; 2008 Apr; 8(4):541-53. PubMed ID: 18352856
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma.
Lu KV; Bergers G
CNS Oncol; 2013 Jan; 2(1):49-65. PubMed ID: 23750318
[TBL] [Abstract][Full Text] [Related]
26. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF.
Di Tacchio M; Macas J; Weissenberger J; Sommer K; Bähr O; Steinbach JP; Senft C; Seifert V; Glas M; Herrlinger U; Krex D; Meinhardt M; Weyerbrock A; Timmer M; Goldbrunner R; Deckert M; Scheel AH; Büttner R; Grauer OM; Schittenhelm J; Tabatabai G; Harter PN; Günther S; Devraj K; Plate KH; Reiss Y
Cancer Immunol Res; 2019 Dec; 7(12):1910-1927. PubMed ID: 31597643
[TBL] [Abstract][Full Text] [Related]
27. The evolving role of antiangiogenic therapies in glioblastoma multiforme: current clinical significance and future potential.
Anthony C; Mladkova-Suchy N; Adamson DC
Expert Opin Investig Drugs; 2019 Sep; 28(9):787-797. PubMed ID: 31356114
[No Abstract] [Full Text] [Related]
28. Angiogenic inhibition in high-grade gliomas: past, present and future.
Jo J; Schiff D; Purow B
Expert Rev Neurother; 2012 Jun; 12(6):733-47. PubMed ID: 22650175
[TBL] [Abstract][Full Text] [Related]
29. Antiangiogenic strategies for treatment of malignant gliomas.
Chi AS; Norden AD; Wen PY
Neurotherapeutics; 2009 Jul; 6(3):513-26. PubMed ID: 19560741
[TBL] [Abstract][Full Text] [Related]
30. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion.
Sorensen AG; Emblem KE; Polaskova P; Jennings D; Kim H; Ancukiewicz M; Wang M; Wen PY; Ivy P; Batchelor TT; Jain RK
Cancer Res; 2012 Jan; 72(2):402-7. PubMed ID: 22127927
[TBL] [Abstract][Full Text] [Related]
31. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
32. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
33. Antiangiogenic therapy in the management of brain tumors: a clinical overview.
Kunnakkat S; Mathew M; Narayana A
Cancer Chemother Pharmacol; 2012 Sep; 70(3):353-63. PubMed ID: 22825032
[TBL] [Abstract][Full Text] [Related]
34. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
35. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
36. Re: angiogenesis and antiangiogenic therapy for malignant gliomas.
Kepes JJ
Brain Tumor Pathol; 2005; 22(1):51. PubMed ID: 18095105
[No Abstract] [Full Text] [Related]
37. Tracking normalization of brain tumor vasculature by magnetic imaging and proangiogenic biomarkers.
Hormigo A; Gutin PH; Rafii S
Cancer Cell; 2007 Jan; 11(1):6-8. PubMed ID: 17222788
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of antiangiogenic drugs in glioblastoma patients: A systematic review and meta-analysis of randomized clinical trials.
Lombardi G; Pambuku A; Bellu L; Farina M; Della Puppa A; Denaro L; Zagonel V
Crit Rev Oncol Hematol; 2017 Mar; 111():94-102. PubMed ID: 28259301
[TBL] [Abstract][Full Text] [Related]
39. Angiogenesis in brain tumours.
Jain RK; di Tomaso E; Duda DG; Loeffler JS; Sorensen AG; Batchelor TT
Nat Rev Neurosci; 2007 Aug; 8(8):610-22. PubMed ID: 17643088
[TBL] [Abstract][Full Text] [Related]
40. Experimental and computational analyses reveal dynamics of tumor vessel cooption and optimal treatment strategies.
Voutouri C; Kirkpatrick ND; Chung E; Mpekris F; Baish JW; Munn LL; Fukumura D; Stylianopoulos T; Jain RK
Proc Natl Acad Sci U S A; 2019 Feb; 116(7):2662-2671. PubMed ID: 30700544
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
